期刊文献+

抗菌药物在持续性血液置换治疗中的应用 被引量:4

The application of antibiotics in patients undergoing continuous renal replacement therapy
原文传递
导出
摘要 目的:探讨不同抗菌药物在持续性血液置换治疗(CRRT)中剂量调整方案及药物代谢动力学的差异。方法:收集相关文献资料,归纳CRRT的患者常用抗生素的剂量调整方案,包括β-内酰胺类、头孢菌素类、碳青霉烯类、万古霉素等,总结各药物在CRRT中的药物代谢动力学特点。结果:对于合并感染的危重症患者,需要根据药物的药代动力学参数和CRRT的模式调整给药方案。由于不同药物的代谢通路和分子量大小的不同,药物推荐剂量也不同。结论:大多数抗菌药物在CRRT中均需要调整给药剂量,不合理的剂量方案可能带来治疗失败或发生不良反应。 Objective: To review the dose adjustment and pharmacokinetic differences of different antibiotics in continuous renal replacement therapy (CRRT). Methods: Researches related the dose adjustment in CRRT patients were collected, including β- lactam penicillium, cephalosporins, carbapenems and vancomycin. Pharmacokinetic characteristics of medicine in CRRT were summarized. Results: It's necessary that dosage adjustment in CRRT should be done according to pharmacokinetic characteristics in critically ill patients with infection. Recommended dosages were different because of different metabolic pathways and variant molecular size. Conclusion: Adjustment the dosage of medication is needed in most antibiotics with CRRT, and unreasonable dosage regimens could result in ineffective treatment or drug adverse reactions.
出处 《临床药物治疗杂志》 2017年第4期11-14,共4页 Clinical Medication Journal
关键词 抗菌药物 持续性血液置换治疗 药物代谢动力学 Antibiontics continuous renal replalement therapy Pharmacokinetic
  • 相关文献

参考文献1

二级参考文献16

  • 1赵彩芸,李家泰,张莉,张朴,刘燕.单次静脉美罗培南在健康人体的药代动力学[J].中国临床药理学杂志,2004,20(3):189-192. 被引量:25
  • 2Alberti C, Brun-Buisson C, Burchardi H,et al. Epidemiology of sepsis and infection in ICU patients from an international muhicen- tre cohort study. Intensive Care Med,2002,28 : 108-121.
  • 3Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA, 2005,294 : 813-818.
  • 4Dandekar PK, Maglio D, Sutherland CA, et al. Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion. Pharmacotherapy, 2003,23 : 988-991.
  • 5Jaruratanasirikul S,Sriwiriyajan S,Punyo J. Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob Agents Chemother, 2005,49 : 1337-1339.
  • 6Valtonen M,Tiula E, Backman JT, et al. Elimination of meropenem during continuous veno-venous haemofiltration and haemodiafiltration in patients with acute renal failure. J Antimicrob Chemother, 2000,45 : 701-704.
  • 7Giles LJ,Jennings AC,Thomson AH,et al. Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafihration. Crit Care Med, 2000,28 : 632-637.
  • 8Krueger WA, Neeser G, Schuster H, et al. Correlation of meropenem plasma levels with pharmacodynamic requirements in critically ill patients receiving continuous veno-venous hemofihralion. Chemotherapy, 2003,49 : 280-286.
  • 9Thalhammer F, Schenk P, Burgmann H, et al. Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration. Antimicrob Agents Chemother, 1998,42 : 2417-2420.
  • 10Krueger WA,Bulitta J, Kinzig-Schippers M, et al. Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers. Antimicrob Agents Chemother,2005,49: 1881-1889.

共引文献13

同被引文献26

引证文献4

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部